Millennium Management LLC Sells 103,269 Shares of Immunocore Holdings plc (NASDAQ:IMCR)

Millennium Management LLC decreased its holdings in shares of Immunocore Holdings plc (NASDAQ:IMCR - Free Report) by 15.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 573,362 shares of the company's stock after selling 103,269 shares during the quarter. Millennium Management LLC owned approximately 1.15% of Immunocore worth $16,914,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Jefferies Financial Group Inc. acquired a new stake in Immunocore in the fourth quarter valued at $4,868,000. Hudson Bay Capital Management LP lifted its stake in Immunocore by 31.5% in the fourth quarter. Hudson Bay Capital Management LP now owns 325,300 shares of the company's stock valued at $9,596,000 after acquiring an additional 78,000 shares during the last quarter. Deep Track Capital LP acquired a new stake in Immunocore in the fourth quarter valued at $15,322,000. Crestline Management LP acquired a new stake in Immunocore in the fourth quarter valued at $736,000. Finally, Cubist Systematic Strategies LLC acquired a new stake in Immunocore in the fourth quarter valued at $3,145,000. Institutional investors and hedge funds own 84.50% of the company's stock.

Insider Buying and Selling

In other Immunocore news, Director Bros. Advisors Lp Baker purchased 807,338 shares of the stock in a transaction that occurred on Monday, March 17th. The shares were acquired at an average cost of $29.72 per share, with a total value of $23,994,085.36. Following the completion of the transaction, the director now owns 2,144,060 shares in the company, valued at $63,721,463.20. The trade was a 60.40% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 10.40% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of analysts have commented on IMCR shares. Oppenheimer increased their price target on shares of Immunocore from $85.00 to $86.00 and gave the company an "outperform" rating in a research note on Thursday, May 8th. JPMorgan Chase & Co. cut their price target on shares of Immunocore from $54.00 to $50.00 and set an "overweight" rating for the company in a research note on Monday, April 14th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Immunocore in a research note on Tuesday. They issued a "buy" rating and a $65.00 price target for the company. Needham & Company LLC reissued a "buy" rating and issued a $71.00 price objective on shares of Immunocore in a research report on Thursday, April 10th. Finally, Mizuho dropped their price objective on shares of Immunocore from $38.00 to $33.00 and set a "neutral" rating on the stock in a research report on Monday, April 7th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $58.89.

Immunocore Stock Performance

Shares of IMCR traded up $0.88 during trading hours on Tuesday, hitting $32.04. The company had a trading volume of 787,427 shares, compared to its average volume of 390,271. The firm has a market cap of $1.60 billion, a price-to-earnings ratio of -33.73 and a beta of 0.75. The business has a fifty day moving average of $29.09 and a 200-day moving average of $29.97. Immunocore Holdings plc has a 12 month low of $23.15 and a 12 month high of $49.05. The company has a quick ratio of 3.76, a current ratio of 3.78 and a debt-to-equity ratio of 1.03.

Immunocore (NASDAQ:IMCR - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.10 EPS for the quarter, topping analysts' consensus estimates of ($0.35) by $0.45. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.84%. The business had revenue of $125.13 million for the quarter, compared to analyst estimates of $108.82 million. During the same period last year, the firm earned ($0.49) earnings per share. Immunocore's revenue for the quarter was up 33.6% compared to the same quarter last year. Equities analysts anticipate that Immunocore Holdings plc will post -0.94 EPS for the current fiscal year.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.